跳至主要内容
临床试验/NCT03100188
NCT03100188已完成不适用

Designer Dialysis: Designing a Peritoneal Dialysis Prescription That Fits a Patient's Lifestyle

Louisiana State University Health Sciences Center in New Orleans0 个研究点目标入组 7 人开始时间: 2015年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
7
主要终点
change in quality of life

研究概览

简要总结

This study aims to use modified peritoneal dialysis prescriptions to achieve adequate clearance and volume removal while decreasing the number of exchanges or time spent on dialysis, evaluating maintenance of residual renal function, and improving quality of life.

详细描述

Patient's currently on peritoneal dialysis at our program can be considered for this study. In order to be enrolled, patients patient's must have significant residual renal function defined as a renal Kt/V >1.0. These patients will then be consented, and if agreeable, the participant's dialysis prescriptions will be modified to decrease their peritoneal dialysis. For patients on continuous ambulatory peritoneal dialysis (CAPD), this may mean less exchanges in a 24 hour period, or less exchanges over the course of the week (does not need to perform exchanges every day). Patients who are continuous cycler peritoneal dialysis (CCPD) will be modified to shorter cycler times, or also less cycles during the course of the week (does not need cycler therapy every day).

Patients will need to continue achieving adequate weekly total Kt/V of greater than or equal to 1.7 as per national recommendations and the clinical guidelines within our unit. This is calculated using the residual renal (RR) Kt/v and the PD Kt/V. Patients will also perform monthly 24 hour urine collections for urinary volume, creatinine clearance, and urea clearance. Adequacy is typically measured every 3 months based on our internal lab requirements, but patients will need to perform adequacy measurements any time their prescription is changed. The investigators will measure monthly labs per routine including albumin, parathyroid hormone (PTH), serum phosphorus, and hemoglobin.

The investigators hypothesize that patients will have a better quality of life (QoL) while on a modified dialysis prescription with less exchanges or less cycler time as assessed by the kidney disease quality of life (KDQOL-36) survey tool. The investigators believe that patients with higher levels of residual renal function (≥ 2 mL/min) can perform fewer peritoneal dialysis exchanges while still achieving and maintaining adequate clearance of solute and appropriate volume removal. The investigators also believe that by maximizing the use of the residual renal function, the investigators can adjust the peritoneal dialysis prescription by decreasing the numbers of manual exchanges per day, decreasing cycler time, or possibly decreasing the number of days of dialysis each week. With the benefit of less dialysis time or exchanges per day, the investigators believe patients will have a decreased "burnout" rate by allowing them to have a better QoL and not feel burdened by the dialysis therapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients on either CAPD or CCPD and had both residual renal (RR) Kt/V ≥ 1.0 and total Kt/V values ≥ 1.7.

排除标准

  • patients who did not meet the values of RR Kt/V and total Kt/V specified above

结局指标

主要结局

change in quality of life

时间窗: at the time of enrollment and again after 12 months

change in survey results of modified KDQOL 36 survey

次要结局

  • change in residual renal kt/v(30 days after enrollment, and then every 3 months for a total of 12 months after enrollment.)
  • change in PD Kt/V(30 days after enrollment, and then every 3 months for a total of 12 months after enrollment.)
  • change in total kt/v(30 days after enrollment, and then every 3 months for a total of 12 months after enrollment.)
  • change in serum albumin(monthly for 12 months after enrollment)
  • change in 24 hour urine output(monthly for 12 months after enrollment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mihran Naljayan

principal investigator

Louisiana State University Health Sciences Center in New Orleans

相似试验